BACKGROUND: Cyanide (CN) toxicity is a serious clinical problem and can occur with sodium nitroprusside (SNP) administration, accidental smoke inhalation, industrial mishaps, and bio-terrorism. In this study, we induced severe CN toxicity independently with SNP or sodium cyanide (NaCN) in a juvenile pig model to demonstrate reversal of severe CN toxicity with a new antidote, sulfanegen sodium, a prodrug of 3-mercaptopyruvate. METHODS: SNP study: A pilot study in 11 anesthetized, mechanically ventilated juvenile pigs allowed us to determine the dose of SNP to induce CN toxicity. Blood CN, serum lactates, and blood gases were monitored. CN toxicity was defined as the occurrence of severe lactic acidosis accompanied by significant elevation in blood CN levels. Based on this pilot study, 8 anesthetized pigs received a high-dose i.v. infusion of SNP (100 mg/h) for 2 hours to induce CN toxicity. They were then randomized to receive either sulfanegen sodium or placebo. Four pigs received 3 doses of sulfanegen sodium (2.5 g i.v.) every hour after induction of severe CN toxicity, and 4 pigs received placebo. NaCN study: A pilot study was conducted in 4 spontaneously ventilating pigs sedated with propofol plus ketamine to demonstrate hemodynamic and metabolic stability for several hours. After this, 6 pigs were similarly sedated and given NaCN in bolus aliquots to produce CN toxicity ultimately resulting in death. Hemodynamics and metabolic variables were followed to define peak CN toxicity. In another group of 6 pigs, severe CN toxicity was induced by this method, and at peak toxicity, the animals were given sulfanegen sodium (2.5 g i.v.) followed by a repeat dose 60 minutes later in surviving animals. RESULTS: SNP study: The pilot study demonstrated the occurrence of a significant increase in blood CN levels (P < 0.05) accompanied by severe lactic acidemia (P < 0.05) in all pigs receiving a high dose of SNP. Administration of the sulfanegen antidote resulted in progressive significant reduction in blood lactate and CN levels with 100% survival (P < 0.05), whereas the placebo-treated pigs deteriorated and did not survive (P < 0.05). NaCN study: NaCN injection resulted in CN toxicity accompanied by severe lactic acidosis and mortality in all the pigs. Sulfanegen sodium reversed this toxicity and prevented mortality in all the pigs treated with this antidote. CONCLUSIONS: CN toxicity can be successfully induced in a juvenile pig model with SNP or NaCN. The prodrug, sulfanegen sodium, is effective in reversing CN toxicity induced by SNP or NaCN.
BACKGROUND:Cyanide (CN) toxicity is a serious clinical problem and can occur with sodium nitroprusside (SNP) administration, accidental smoke inhalation, industrial mishaps, and bio-terrorism. In this study, we induced severe CNtoxicity independently with SNP or sodium cyanide (NaCN) in a juvenile pig model to demonstrate reversal of severe CNtoxicity with a new antidote, sulfanegen sodium, a prodrug of 3-mercaptopyruvate. METHODS: SNP study: A pilot study in 11 anesthetized, mechanically ventilated juvenile pigs allowed us to determine the dose of SNP to induce CNtoxicity. Blood CN, serum lactates, and blood gases were monitored. CNtoxicity was defined as the occurrence of severe lactic acidosis accompanied by significant elevation in blood CN levels. Based on this pilot study, 8 anesthetized pigs received a high-dose i.v. infusion of SNP (100 mg/h) for 2 hours to induce CNtoxicity. They were then randomized to receive either sulfanegen sodium or placebo. Four pigs received 3 doses of sulfanegen sodium (2.5 g i.v.) every hour after induction of severe CNtoxicity, and 4 pigs received placebo. NaCN study: A pilot study was conducted in 4 spontaneously ventilating pigs sedated with propofol plus ketamine to demonstrate hemodynamic and metabolic stability for several hours. After this, 6 pigs were similarly sedated and given NaCN in bolus aliquots to produce CNtoxicity ultimately resulting in death. Hemodynamics and metabolic variables were followed to define peak CNtoxicity. In another group of 6 pigs, severe CNtoxicity was induced by this method, and at peak toxicity, the animals were given sulfanegen sodium (2.5 g i.v.) followed by a repeat dose 60 minutes later in surviving animals. RESULTS: SNP study: The pilot study demonstrated the occurrence of a significant increase in blood CN levels (P < 0.05) accompanied by severe lactic acidemia (P < 0.05) in all pigs receiving a high dose of SNP. Administration of the sulfanegen antidote resulted in progressive significant reduction in blood lactate and CN levels with 100% survival (P < 0.05), whereas the placebo-treated pigs deteriorated and did not survive (P < 0.05). NaCN study: NaCN injection resulted in CNtoxicity accompanied by severe lactic acidosis and mortality in all the pigs. Sulfanegen sodium reversed this toxicity and prevented mortality in all the pigs treated with this antidote. CONCLUSIONS:CNtoxicity can be successfully induced in a juvenile pig model with SNP or NaCN. The prodrug, sulfanegen sodium, is effective in reversing CNtoxicity induced by SNP or NaCN.
Authors: Daune L Crankshaw; David J W Goon; Jacquie E Briggs; David DeLong; Michael Kuskowski; Steven E Patterson; Herbert T Nagasawa Journal: Toxicol Lett Date: 2007-10-10 Impact factor: 4.372
Authors: Matthew Brenner; Jae G Kim; Jangwoen Lee; Sari B Mahon; Daniel Lemor; Rebecca Ahdout; Gerry R Boss; William Blackledge; Lauren Jann; Herbert T Nagasawa; Steven E Patterson Journal: Toxicol Appl Pharmacol Date: 2010-08-10 Impact factor: 4.219
Authors: Frédéric J Baud; Stephen W Borron; Bruno Mégarbane; Hervé Trout; Frédéric Lapostolle; Eric Vicaut; Marcel Debray; Chantal Bismuth Journal: Crit Care Med Date: 2002-09 Impact factor: 7.598
Authors: Steven E Patterson; Bryant Moeller; Herbert T Nagasawa; Robert Vince; Daune L Crankshaw; Jacquie Briggs; Michael W Stutelberg; Chakravarthy V Vinnakota; Brian A Logue Journal: Ann N Y Acad Sci Date: 2016-06-16 Impact factor: 5.691
Authors: Michael W Stutelberg; Chakravarthy V Vinnakota; Brendan L Mitchell; Alexandre R Monteil; Steven E Patterson; Brian A Logue Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2014-01-18 Impact factor: 3.205
Authors: Bryant M Moeller; Daune L Crankshaw; Jacquie Briggs; Herbert T Nagasawa; Steven E Patterson Journal: Toxicol Lett Date: 2017-04-12 Impact factor: 4.372
Authors: Eleanor M Summerhill; Gary W Hoyle; Sven-Eric Jordt; Bronwen J Jugg; James G Martin; Sadis Matalon; Steven E Patterson; David J Prezant; Alfred M Sciuto; Erik R Svendsen; Carl W White; Livia A Veress Journal: Ann Am Thorac Soc Date: 2017-06
Authors: Steven E Patterson; Alexandre R Monteil; Jonathan F Cohen; Daune L Crankshaw; Robert Vince; Herbert T Nagasawa Journal: J Med Chem Date: 2013-01-30 Impact factor: 7.446
Authors: Daniel G Hottinger; David S Beebe; Thomas Kozhimannil; Richard C Prielipp; Kumar G Belani Journal: J Anaesthesiol Clin Pharmacol Date: 2014-10
Authors: Adrian Thompson; Michael Dunn; Robert D Jefferson; Kosala Dissanayake; Frances Reed; Rachael Gregson; Stephen Greenhalgh; R Eddie Clutton; Peter G Blain; Simon Hl Thomas; Michael Eddleston Journal: Clin Toxicol (Phila) Date: 2019-08-07 Impact factor: 4.467